secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000882095-24-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2 revenue $7.0B (+5%), Non-GAAP EPS $2.01; raised Non-GAAP FY guidance to $3.60-$3.90
--------------------------------------------------------------------------------

- Q2 2024 revenue $7.0B (+5% YoY); GAAP diluted EPS $1.29 (prior $0.83), Non-GAAP diluted EPS $2.01 (prior $1.34).
- HIV sales +3% to $4.7B; Biktarvy sales +8% to $3.2B; Oncology +15% to $841M; Trodelvy +23% to $320M.
- Full-year 2024 product sales guidance unchanged at $27.1-27.5B; non-GAAP EPS guidance raised to $3.60-$3.90; GAAP EPS lowered to $0.00-$0.30.
- Phase 3 lenacapavir for HIV prevention showed 100% efficacy in cisgender women; CymaBay acquisition closed for $3.9B.
- Product gross margin 77.7% GAAP, 86.0% non-GAAP; operating cash flow $1.3B after $1.2B transition tax payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000020/0000882095-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000020/gild-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000882095-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer